EP 2771329 B1 20160316 - NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES
Title (en)
NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES
Title (de)
NEUE DISUBSTITUIERTE 3,4-DIAMINO-3-CYCLOBUTEN-1,2-DION-VERBINDUNGEN ZUR VERWENDUNG BEI DER BEHANDLUNG CHEMOKINVERMITTELTER ERKRANKUNGEN
Title (fr)
NOUVEAUX COMPOSÉS DI-SUBSTITUÉS DE LA DIAMINO-3,4-CYCLOBUTÈNE-3-DIONE-1,2 UTILES DANS LE TRAITEMENT DE PATHOLOGIES MÉDIÉES PAR DES CHIMIOKINES
Publication
Application
Priority
- US 201161552940 P 20111028
- FR 1159833 A 20111028
- FR 2012052478 W 20121026
Abstract (en)
[origin: WO2013061004A1] The present invention relates to novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to the following general formula (I): , to the pharmaceutical compositions containing these compounds and also to the use of these compounds and of these compositions for the treatment of chemokine-mediated diseases.
IPC 8 full level
C07D 307/14 (2006.01); A61K 31/341 (2006.01); A61K 31/381 (2006.01); A61K 31/4025 (2006.01); A61P 11/00 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01); C07D 407/06 (2006.01); C07D 409/06 (2006.01); C07D 409/14 (2006.01)
CPC (source: CN EP US)
A61K 31/341 (2013.01 - EP US); A61K 31/381 (2013.01 - EP US); A61K 31/4025 (2013.01 - EP US); A61P 1/04 (2017.12 - EP); A61P 11/00 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/04 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/00 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 307/14 (2013.01 - CN EP US); C07D 307/16 (2013.01 - EP US); C07D 307/52 (2013.01 - CN); C07D 307/54 (2013.01 - EP US); C07D 407/06 (2013.01 - CN EP US); C07D 409/06 (2013.01 - CN EP US); C07D 409/14 (2013.01 - CN EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2013061004 A1 20130502; WO 2013061004 A8 20140417; AU 2012328198 A1 20140403; BR 112014009889 A2 20170425; CA 2848263 A1 20130502; CN 103906738 A 20140702; CN 103906738 B 20160907; CY 1117705 T1 20170517; DK 2771329 T3 20160606; EP 2771329 A1 20140903; EP 2771329 B1 20160316; ES 2569053 T3 20160506; FR 2981935 A1 20130503; FR 2981935 B1 20150807; HR P20160608 T1 20160701; HU E029128 T2 20170228; IN 2273CHN2014 A 20150619; JP 2014530894 A 20141120; JP 6068486 B2 20170125; KR 20140090168 A 20140716; MX 2014003958 A 20140827; MX 342924 B 20161019; PL 2771329 T3 20160930; PT 2771329 E 20160617; RS 54775 B1 20161031; RU 2014121390 A 20151210; SI 2771329 T1 20160729; SM T201600151 B 20160701; US 2014296254 A1 20141002; US 2016362403 A1 20161215; US 9388149 B2 20160712; US 9580412 B2 20170228; ZA 201401678 B 20150429
DOCDB simple family (application)
FR 2012052478 W 20121026; AU 2012328198 A 20121026; BR 112014009889 A 20121026; CA 2848263 A 20121026; CN 201280052911 A 20121026; CY 161100489 T 20160602; DK 12791825 T 20121026; EP 12791825 A 20121026; ES 12791825 T 20121026; FR 1159833 A 20111028; HR P20160608 T 20160606; HU E12791825 A 20121026; IN 2273CHN2014 A 20140325; JP 2014537704 A 20121026; KR 20147011443 A 20121026; MX 2014003958 A 20121026; PL 12791825 T 20121026; PT 12791825 T 20121026; RS P20160367 A 20121026; RU 2014121390 A 20121026; SI 201230577 A 20121026; SM 201600151 T 20160531; US 201214354033 A 20121026; US 201615175363 A 20160607; ZA 201401678 A 20140306